Can Vitamin C Be Synthesized by the Liver?

Vitamin C, chemically known as L-ascorbic acid, is essential for collagen synthesis, immune function, and antioxidant defense. Most animals produce it internally and never need to obtain it from food. Humans, other primates, guinea pigs, and a handful of other species are the notable exceptions — they must acquire the compound entirely through diet or supplementation because their bodies have permanently lost the ability to make it.

The question of whether the human liver can synthesize vitamin C is not a matter of debate in biochemistry: it cannot. The liver does play a central role in vitamin C metabolism in species that retain synthesis capability, and understanding why that pathway is absent in humans — and what the liver does instead — clarifies both the biology of the vitamin and why dietary intake matters at all.

How Vitamin C Synthesis Works in the Liver — and Why the Human Version Is Broken

In mammals capable of endogenous synthesis, vitamin C is produced through a four-enzyme pathway that begins with glucose. The liver converts glucose to glucuronic acid, then to gulonolactone, then to 2-keto-L-gulonolactone, and finally to L-ascorbic acid. The last step is catalyzed by an enzyme called L-gulonolactone oxidase (GULO). In rats, mice, and most other mammals, this pathway operates continuously, and output increases substantially under physiological stress — infection, injury, and oxidative load all upregulate GULO activity.

In humans, the GULO gene exists in the genome but is nonfunctional. It carries multiple inactivating mutations — frameshifts, deletions, and stop codons — accumulated over roughly 60 million years of primate evolution. Because ancestral primates consumed diets rich in fresh fruit and plant matter, dietary vitamin C was reliably available, and there was no selective pressure to preserve a costly biosynthetic pathway. The result is a pseudogene: the DNA sequence is present, but no functional GULO enzyme is produced, so the final conversion to ascorbic acid never occurs.

The liver still processes vitamin C extensively once it arrives from the diet — it stores a modest fraction, participates in its recycling between oxidized and reduced forms, and handles its eventual catabolism — but it cannot manufacture the molecule from scratch. That distinction is the core answer to the synthesis question.

Which Compounds, Organs, and Transporters Are Involved

The GULO pseudogene. Located on chromosome 8 in humans, this remnant gene retains recognizable sequence homology to functional GULO genes in other mammals but produces no active enzyme. Its presence is used by evolutionary biologists as molecular evidence of shared ancestry among primates that lost synthesis capacity.

The small intestine. Because humans cannot synthesize vitamin C, the gastrointestinal tract is the primary entry point. Absorption occurs predominantly in the proximal small intestine — the duodenum and jejunum. Two sodium-dependent vitamin C transporters, SVCT1 and SVCT2, move ascorbic acid across intestinal epithelial cells and into the bloodstream. SVCT1 is expressed heavily in intestinal and kidney epithelium and governs bulk absorption and renal reabsorption. SVCT2 is more widely distributed and handles uptake into metabolically active tissues, including the adrenal glands and brain, which maintain the highest tissue concentrations in the body. A fuller account of how the body actually processes vitamin C after absorption covers these transport dynamics in detail.

The liver's actual role. Although the liver cannot synthesize ascorbic acid, it is a significant storage depot and metabolic site. Hepatocytes take up ascorbic acid via SVCT2, and the liver maintains a meaningful tissue pool. The liver also expresses glutathione-dependent enzymes that regenerate reduced ascorbic acid from its oxidized form, dehydroascorbic acid (DHAA), effectively recycling the vitamin before it is irreversibly degraded.

The kidneys. Renal reabsorption via SVCT1 in proximal tubule cells is the primary mechanism by which the body conserves vitamin C and regulates plasma concentration. When plasma levels are low, reabsorption is near-complete. When plasma levels are high — as occurs with large supplemental doses — the transporter becomes saturated and excess ascorbate is excreted in urine, which is why urinary output of the vitamin rises sharply at higher intakes.

Ascorbate and dehydroascorbic acid (DHAA). Vitamin C cycles between its reduced form (ascorbic acid) and its oxidized form (DHAA). DHAA can enter cells through glucose transporters (GLUT1, GLUT3, GLUT4) and is then reduced back to ascorbic acid intracellularly. This dual-transport system allows tissues to accumulate ascorbate even when extracellular concentrations are relatively low.

Where Vitamin C Absorption Breaks Down or Produces Unexpected Results

Saturable absorption at the intestine. SVCT1 transport is concentration-dependent and saturable. At low-to-moderate dietary intakes, a large fraction of ingested ascorbic acid is absorbed. As intake increases, the proportion absorbed falls substantially — a phenomenon called dose-dependent absorption. At very high single doses, a majority of the ingested amount may pass unabsorbed into the colon, where it draws water osmotically and can cause loose stools. This is not a sign of toxicity but a predictable consequence of transporter saturation.

The plasma concentration ceiling. Plasma ascorbate concentration does not rise indefinitely with increased intake. It reaches a functional ceiling determined by intestinal absorption capacity, tissue uptake, and renal threshold. This ceiling means that the relationship between dose and circulating concentration is nonlinear — doubling intake does not double plasma levels once the transporters are operating near capacity.

Oxidative stress and accelerated depletion. In species that synthesize vitamin C endogenously, GULO output can increase many-fold in response to infection or injury. Humans have no equivalent upregulation mechanism. Under conditions of high oxidative stress — illness, heavy exercise, smoking — tissue ascorbate is consumed more rapidly, but the body cannot compensate by making more. Intake from diet or supplements remains the only source.

Bioavailability variation across formulations. Ascorbic acid, sodium ascorbate, calcium ascorbate, and ascorbate combined with bioflavonoids are all marketed as vitamin C sources. Evidence from bioavailability studies shows that plasma response differs modestly across these forms, though the differences are generally smaller than the variation introduced by dose size and individual absorptive capacity. The form of vitamin C in a supplement label does not straightforwardly predict the plasma concentration that results.

Interaction with iron absorption. Ascorbic acid in the gut lumen reduces ferric iron (Fe³⁺) to ferrous iron (Fe²⁺), which is the form absorbed by the divalent metal transporter DMT1. This is a well-characterized interaction, but it also means that vitamin C consumed alongside high-iron foods or supplements substantially alters iron uptake — an effect that is not reflected anywhere on a vitamin C supplement label.

What a Vitamin C Supplement Label Shows — and What It Does Not

A vitamin C supplement label in the United States is required to state the form of ascorbate used, the amount per serving in milligrams, and the percent Daily Value based on the reference value established by the FDA. These disclosures are governed by the Nutrition Labeling regulations under DSHEA and its implementing rules. The label confirms what is in the bottle at the time of manufacture, within the tolerances allowed by the FDA's current Good Manufacturing Practice (cGMP) regulations for dietary supplements.

What the label does not show is bioavailability. No label is required to report — and none can guarantee — what fraction of the stated dose will be absorbed by any individual. Absorption depends on the consumer's current plasma ascorbate status, gut health, the presence of other food components, and the dose size relative to transporter saturation, none of which are captured in the Supplement Facts panel.

The label also does not indicate whether the product has been tested by an independent third-party organization for label accuracy or absence of contaminants. A third-party certification seal, if present, attests that the product was tested and found to contain what the label states — it is not an FDA approval. No dietary supplement undergoes premarket approval by the FDA; the agency reviews safety and labeling after products are already on the market. Readers interested in how that regulatory structure operates can find a detailed account of how the supplement industry is actually regulated in the quality section of this site.

Structure/function claims such as "supports immune health" or "provides antioxidant support" are permitted on vitamin C labels under DSHEA, provided the manufacturer notifies the FDA and includes a disclaimer that the statement has not been evaluated by the FDA and that the product is not intended to diagnose, treat, cure, or prevent any disease. That disclaimer is a legal requirement, not optional language — its presence on a label signals that the product is a dietary supplement, not a drug.

The loss of functional GULO in the human lineage is one of the more consequential mutations in primate evolutionary history — it transferred full responsibility for ascorbate supply from an internal biosynthetic pathway to the diet, making the liver a processor and recycler of vitamin C rather than its manufacturer. The biochemistry of that shift, and the transport machinery that replaced endogenous synthesis, shapes how ascorbic acid moves through the body from the moment it is swallowed.

Note: This explains how supplements work. This statement has not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for advice from a physician, pharmacist, or registered dietitian.